A phase 1 study of tazarotene in adults with advanced cancer

Tazarotene is an acetylenic retinoid which is metabolised to tazarotenic acid and which binds selectively to the retinoid receptors RARβ and RARγ. The safety, toxicity and pharmacokinetics of oral tazarotene were determined over 12 weeks of treatment in 34 patients with advanced cancer. Commonly see...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, P H, Burnett, R D, Fainaru, I, Nadolny, P, Walker, P, Yu, Z, Tang-Liu, D, Ganesan, T S, Talbot, D C, Harris, A L, Rustin, G J S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394470/
https://www.ncbi.nlm.nih.gov/pubmed/12942109
http://dx.doi.org/10.1038/sj.bjc.6601169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394470/
https://www.ncbi.nlm.nih.gov/pubmed/12942109
http://dx.doi.org/10.1038/sj.bjc.6601169

Ejemplares similares